Nephros (NEPH) Competitors $4.08 +0.05 (+1.24%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$4.18 +0.10 (+2.45%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. CVRX, LNSR, AVR, PDEX, RCEL, INFU, LUCD, LAKE, PTHL, and OBIOShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include CVRx (CVRX), LENSAR (LNSR), Anteris Technologies Global (AVR), Pro-Dex (PDEX), Avita Medical (RCEL), InfuSystem (INFU), Lucid Diagnostics (LUCD), Lakeland Industries (LAKE), Pheton (PTHL), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors CVRx LENSAR Anteris Technologies Global Pro-Dex Avita Medical InfuSystem Lucid Diagnostics Lakeland Industries Pheton Orchestra BioMed Nephros (NASDAQ:NEPH) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Does the media favor NEPH or CVRX? In the previous week, Nephros and Nephros both had 1 articles in the media. CVRx's average media sentiment score of 0.80 beat Nephros' score of 0.00 indicating that CVRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in NEPH or CVRX? 41.1% of Nephros shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 18.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is NEPH or CVRX more profitable? Nephros has a net margin of 5.16% compared to CVRx's net margin of -97.49%. Nephros' return on equity of 9.43% beat CVRx's return on equity.Company Net Margins Return on Equity Return on Assets Nephros5.16% 9.43% 7.20% CVRx -97.49%-79.04%-42.37% Do analysts recommend NEPH or CVRX? Nephros currently has a consensus price target of $5.00, indicating a potential upside of 22.55%. CVRx has a consensus price target of $14.50, indicating a potential upside of 120.03%. Given CVRx's higher probable upside, analysts plainly believe CVRx is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CVRx 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more risk & volatility, NEPH or CVRX? Nephros has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Which has preferable earnings and valuation, NEPH or CVRX? Nephros has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.05$70K$0.0758.29CVRx$51.29M3.35-$59.97M-$2.18-3.02 SummaryCVRx beats Nephros on 8 of the 15 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.72M$10.52B$5.52B$9.02BDividend YieldN/A2.07%5.24%4.05%P/E Ratio58.2916.9127.2220.08Price / Sales3.0528.86381.5993.26Price / Cash201.3923.9726.2128.59Price / Book5.043.637.945.55Net Income$70K$235.43M$3.17B$248.49M7 Day Performance1.24%-0.32%1.79%4.87%1 Month Performance21.43%-0.33%1.27%6.63%1 Year Performance100.99%-10.48%33.57%20.38% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros0.8398 of 5 stars$4.08+1.2%$5.00+22.5%+96.2%$42.72M$14.16M58.2930Positive NewsHigh Trading VolumeCVRXCVRx2.7436 of 5 stars$5.88+1.0%$14.50+146.6%-46.7%$151.74M$51.29M-2.70160LNSRLENSAR1.3568 of 5 stars$13.17+3.2%$15.00+13.9%+187.2%$150.47M$53.49M-2.72110AVRAnteris Technologies GlobalN/A$3.79-6.7%$16.50+335.4%N/A$146.41M$2.70M0.00138Positive NewsPDEXPro-Dex2.4553 of 5 stars$43.64-2.8%$56.00+28.3%+164.9%$146.36M$53.84M15.59140Positive NewsHigh Trading VolumeRCELAvita Medical0.855 of 5 stars$5.29-2.9%$16.50+211.9%-35.9%$144.07M$64.25M-2.42130INFUInfuSystem1.9131 of 5 stars$6.24+2.0%$13.00+108.3%N/A$131.14M$137.58M104.02410High Trading VolumeLUCDLucid Diagnostics2.1475 of 5 stars$1.15-1.7%$3.55+208.7%+31.8%$126.58M$4.35M-0.8670Positive NewsLAKELakeland Industries4.8193 of 5 stars$13.61+3.3%$26.00+91.0%-37.0%$125.40M$167.21M-4.522,100Positive NewsHigh Trading VolumePTHLPhetonN/A$18.39+0.8%N/AN/A$120.06M$450K0.0011High Trading VolumeOBIOOrchestra BioMed2.6209 of 5 stars$2.68-3.6%$14.20+429.9%-64.2%$106.51M$2.64M-1.514High Trading Volume Related Companies and Tools Related Companies CVRx Competitors LENSAR Competitors Anteris Technologies Global Competitors Pro-Dex Competitors Avita Medical Competitors InfuSystem Competitors Lucid Diagnostics Competitors Lakeland Industries Competitors Pheton Competitors Orchestra BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
